Venglustat, a novel glucosylceramide synthase inhibitor, in patients at risk of rapidly progressing ADPKD: primary results of a double-blind, placebo-controlled, phase 2/3 randomized clinical trial

Gansevoort, R.T., Hariri, A., Minini, P. et al. (11 more authors) (2022) Venglustat, a novel glucosylceramide synthase inhibitor, in patients at risk of rapidly progressing ADPKD: primary results of a double-blind, placebo-controlled, phase 2/3 randomized clinical trial. American Journal of Kidney Diseases. S0272-6386(22)01079. ISSN 0272-6386

Abstract

Metadata

Authors/Creators:
  • Gansevoort, R.T.
  • Hariri, A.
  • Minini, P.
  • Ahn, C.
  • Chapman, A.B.
  • Horie, S.
  • Knebelmann, B.
  • Mrug, M.
  • Ong, A.C.M. ORCID logo https://orcid.org/0000-0002-7211-5400
  • Pei, Y.P.C.
  • Torres, V.E.
  • Modur, V.
  • Antonshchuk, I.
  • Perrone, R.D.
Copyright, Publisher and Additional Information: © 2022 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Autosomal dominant polycystic kidney disease; glomerular filtration rate; total kidney volume; venglustat
Dates:
  • Accepted: 25 October 2022
  • Published (online): 16 December 2022
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Infection, Immunity and Cardiovascular Disease
Funding Information:
FunderGrant number
AVENTIS PHARMA LIMITEDUNSPECIFIED
Depositing User: Symplectic Sheffield
Date Deposited: 10 Jan 2023 16:13
Last Modified: 10 Jan 2023 16:13
Published Version: http://dx.doi.org/10.1053/j.ajkd.2022.10.016
Status: Published online
Publisher: Elsevier BV
Refereed: Yes
Identification Number: https://doi.org/10.1053/j.ajkd.2022.10.016
Related URLs:

Download

Export

Statistics